Abstract
Heart failure is an ambiguous technical terminology. It can either refer to the presence of ventricular dysfunction or a decompensated state with symptoms and signs of clinical congestion. Diagnostic criteria for congestive heart failure, called the Framingham criteria, has not been changed for approximately half a century; the therapeutic strategy, however, has been modified considerably, resulting in improved management of congestion and consequent relief of symptoms and signs in heart failure patients. Ironically, that makes the term “heart failure” even more complex and obscure. Chronic heart failure is a new concept that was constructed based on NYHA (New York Heart Association) functional classification to evaluate the degree of symptoms and heart failure stages as per the degree of myocardial remodeling due to neurohumoral activation. This covers all states of heart failure and provides the appropriate management for patients in each stage. A better understanding of the concept of chronic heart failure is beneficial in the clinical management of patients with this condition, not only for cardiologists but also for all attending physicians.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med. 1971;285:1441–6.
Editorial. Major changes made by Criteria Committee of The New York Heart Association. Circulation. 1974;49:390.
Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.
Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18.
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced leftventricular ejection fractions. N Engl J Med. 1992;327:685–91.
The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843–8.
Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5:669–77.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.
Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308:2108–17.
Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015;20:193–201.
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92.
Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One. 2014;9:e90555.
Seidl K, Rameken M, Vater M, Senges J. Cardiac resynchronization therapy in patients with chronic heart failure: pathophysiology and current experience. Am J Cardiovasc Drugs. 2002;2:219–26.
Inage T, Yoshida T, Hiraki T, et al. Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment. Europace. 2008;10:379–83.
Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol. 2005;46:1875–82.
Elefteriades JA, Tolis G Jr, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411–7.
Iskandrian S, Gioia G, Pancholy S, Dileva K, Heo J, Iskandrian AS. Prognosis of patients with severe left ventricular dysfunction after coronary artery bypass grafting. Am J Cardiol. 1996;77:199–200.
Carr JA, Haithcock BE, Paone G, Bernabei AF, Silverman NA. Long-term outcome after coronary artery bypass grafting in patients with severe left ventricular dysfunction. Ann Thorac Surg. 2002;74:1531–6.
Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1356–63.
Horskotte D, Schulte HD, Bircks W, Strauer BE. The effect of chordal preservation on late outcome after mitral valve replacement: a randomized study. J Heart Valve Dis. 1993;2:150–8.
Friedrich EB, Bohm M. Management of end stage heart failure. Heart. 2007;93:626–31.
Nakatani T, Fukushima N, Ono M, et al. The registry report of heart transplantation in Japan (1999–2013). Circ J. 2014;78:2604–9.
Fukushima N, Ono M, Saito S, et al. Heart donation in Japan before and after the revision of the Japanese Transplantation Act. Transplant Proc. 2014;46:2050–3.
Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, et al. Preoperative INTERMACS profiles determine postoperative outcomes in critically ill patients undergoing emergency heart transplantation: analysis of the Spanish National Heart Transplant Registry. Circ Heart Fail. 2013;6:763–72.
Saito S, Yamazaki K, Nishinaka T, et al. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. J Heart Lung Transplant. 2014;33:599–608.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Japan
About this chapter
Cite this chapter
Kato, M. (2018). The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation. In: Sato, N. (eds) Therapeutic Strategies for Heart Failure. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56065-4_1
Download citation
DOI: https://doi.org/10.1007/978-4-431-56065-4_1
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56063-0
Online ISBN: 978-4-431-56065-4
eBook Packages: MedicineMedicine (R0)